Table 4.
Stratification analysis of the methylation prognostic model.
| Subgroup | Entire EC cohort |
Test EC cohort |
||||
|---|---|---|---|---|---|---|
| No. of Patients | HR (95% CI) | P value | No. of Patients | HR (95% CI) | P value | |
| Age | ||||||
| ≤60 | 132 | 16.90 (3.90–73.20) | 3.58E-09 | 45 | Inf | 7.09E-08 |
| >60 | 290 | 8.32 (4.86–14.24) | 1.92E-14 | 96 | 8.97 (3.06–26.32) | 2.82E-06 |
| FIGO stage | ||||||
| Early stage | 299 | 7.11 (3.00–16.89) | 2.70E-09 | 103 | 8.37 (1.60–43.84) | 2.56E-04 |
| Advanced stage | 123 | 11.20 (6.10–20.55) | 5.07E-09 | 38 | 19.68 (6.05–64.02) | 4.50E-05 |
| Histological type | ||||||
| EEA | 303 | 9.80 (4.15–23.12) | 8.33E-15 | 104 | 8.90 (0.89–88.70) | 1.63E-04 |
| SEA | 98 | 6.16 (3.03–12.53) | 5.46E-04 | 29 | Inf | 7.09E-03 |
| MSE | 21 | 14.03 (0.72–272.79) | 7.24E-05 | 8 | Inf | 4.31E-02 |
| Histologic grade | ||||||
| G1/G2 | 151 | 13.04 (1.70–100.08) | 1.84E-07 | 52 | 13.67 (0.06–3338.65) | 1.18E-02 |
| G3 | 271 | 8.39 (5.03–14.00) | 1.06E-13 | 89 | 15.15 (5.44–42.22) | 5.92E-09 |
Advanced stage: I/II stage; Early stage: III/IV stage; EEA: Endometrioid endometrial adenocarcinoma; MSE: Mixed serous and endometrioid; SEA: Serous endometrial adenocarcinoma.